Influenza A and B are the most common causes of respiratory tract-restricted acute viral disease. Each year, it is estimated that around 16% of children aged 5 to 17 are hospitalized. Baloxavir Marboxil has the potential to be an innovative alternative to the existing standard of therapy for these individuals.